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Abstract Tyrosine phosphorylation has been reported to be an 
early event required for APO-1/Fas(CD95) signalling in lympho- 
cytes [Eischen, C.M., Dick, C.J. and Leibson, P.J. (1994) 
J. Immunol. 153, 1947-1954]. We have compared two mutant 
Jurkat cells, one largely deficient in expression of CD45 (J45.01) 
and a second one deficient in expression of p56 ~ck (JCaM1.6) with 
wild type Jurkat cells for their ability to undergo APO-l-induced 
apoptosis. No significant difference was observed among the three 
cell lines. In the mutant Jurkat cells APO-1 triggering did not 
result in increased tyrosine phosphorylation of cytosolic proteins. 
Furthermore, herbimycin A did not inhibit but rather augmented 
apoptosis at concentrations which effectively degraded the src 
related kinases lck and fyn. The data suggest hat APO-l-medi- 
ated signalling is independent from src kinases and CD45. 
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1. Introduction 
Apoptosis plays a role in embryogenesis, metamorphosis, 
tissue atrophy, neural network formation, tumor regression 
and is essential for normal development of the immune system 
[1--4]. Apoptosis can be mediated via the APO-1/Fas(CD95) 
receptor, a member of the nerve growth factor (NGF)/tumor 
necrosis factor (TNF) receptor superfamily [5,6]. All members 
of this superfamily are characterized by cysteine-fich motives 
of about 40 amino acids located in the extracellular portion of 
the receptors. 
The cytoplasmic region of human APO-1 consists of 145 
amino acids and does not contain any known consensus se- 
quences for an enzymatic function or binding sites for so far 
known signalling molecules. However, it has a homology to the 
intracellular death domain of the TNF type I receptor which 
has also been shown to be capable to transduce cytotoxic sig- 
nals into the cells [7,8]. 
Recent studies employing inhibitors of protein tyrosine ki- 
nases (PTK) suggested that certain forms of apoptosis might 
require activation of PTKs [9-11]. Thus, Eischen et al. reported 
that activation of PTKs represents an early signal required for 
APO-l-mediated signalling in human lymphocytes [11]. The 
major PTKs known to date to be required for receptor-medi- 
ated signalling events in human lymphocytes are two members 
of the src family of protein tyrosine kinases, p56 ~k and p59 fyn. 
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Abbreviations: APO-1L, APO-1 ligand; PBS, phosphate-buffered sa- 
line; PTK, protein tyrosine kinase; PTPase, protein tyrosine phosphat- 
ase; MAPK, MAP kinase; Herb. A, herbimycin A. 
Both PTKs are involved in signalling via the TCR/CD3 com- 
plex and a number of accessory receptors [12-15]. There is now 
compelling evidence that the enzymatic activity of lck and fyn 
is regulated by the protein tyrosine phosphatase (PTPase) 
CD45 [15,16]. Expression of CD45 has been proven to be a 
prerequisite for e.g. TCR/CD3-mediated activation of the PTK 
pathway in human lymphocytes [17]. It was therefore important 
to determine whether src-related PTKs and CD45 might also 
be involved in APO-l-mediated signalling. Using two mutant 
Jurkat cell lines which have previously been demonstrated to 
be impaired in TCR/CD3 signalling due to altered expression 
of p56 lck and CD45, respectively, we show that the signals 
initiated by APO-1 do not depend on expression of either src- 
related PTKs or CD45. This assumption is further supple- 
mented by data which demonstrate hat the classical PTK in- 
hibitor herbimycin A does not inhibit but rather augments 
APO-l-mediated apoptosis in wild type Jurkat cells. 
2. Materials and methods 
2.1. Cells 
The leukemic T-cell ine Jurkat and its mutants were maintained in
RPMI 1640 (Gibco Biocult, Eggenheim, Germany) 10 mM HEPES, pH 
7.3, 10% FCS (Conco, Wiesbaden, Germany), 100 U/ml penicillin, and 
100 pg/ml streptomycin (Gibco) in 5% CO2. The CD45 deficient Jurkat 
mutant J45.01 [18] and the Jurkat mutant JCaM1.6 which lacks expres- 
sion of p561ok [13] were kindly provided by Drs. G. Koretzky (University 
of Iowa, IO) and A. Weiss (UCSF, CA), respectively. 
2.2. Antibodies and reagents 
The mouse monoclonal ntibody (mAb) anti-APO-1 (IgG3, x) recog- 
nizes an epitope on the extracellular part of APO-1 [19]. OKT3 (IgG2a) 
is specific for CD3. Monoclonal antibody AICD45.2 (IgG1) reacts with 
CD45 [20]. The anti-ERK-I-III (MAPK) rabbit Ab and the biotinylated 
anti-phosphotyrosine mAb 4G10 were obtained from UBI (Lake 
Placid, NY). The anti-p561ok rabbit antiserum was kindly provided by 
Dr. A. Veillette (McGill University-, Montreal, Canada) and the rabbit 
antiserum Ab cst-1 (directed at a common determinant a the C-termi- 
nus of p59 fyn, p62 c-yes and p60 e'er°) was a generous gift from Dr. S. 
Courtneidge (EMBL, Heidelberg, Germany). All chemicals used were 
of analytical grade and purchased from Merck (Darmstadt, Germany) 
or Sigma (St. Louis, MO). 
2.3. Western blotting, pervanadate treatment and anti-phosphotyrosine 
analysis 
10 7 cells/ml were incubated in the presence or absence of 10 pg/ml 
antibody at 37°C. Stimulation was stopped by addition of 200 pl of hot 
reducing standard SDS sample buffer. The samples were cooled on ice. 
20 ffi were separated by 12.5% SDS-PAGE. For pervanadate treatment 
2 x 10 6 cells were incubated with 0.1 or 1 mM sodium pervanadate and 
1 mM H2Oz for 15 min at 37°C. Cells were washed twice in ice-cold TBS 
and lysed in a 1% Triton X-100 containing buffer. Following SDS- 
PAGE samples were transferred onto Hybond nitrocellulose membrane 
(Amersham, Braunschweig, Germany), which was blocked with 5% 
(w/v) dry milk in PBS for at least 1 h and then washed with PBS 
containing 0.02% (v/v) Tween-20 (PBS/Tween). The blot was either 
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incubated with 10 /lg/ml biotinylated 4G10, 1:1000 (v/v) anti-lck, 
1 ktg/ml cst-1 or 1 ¢tg/ml anti-MAPK antibody for 16 h at 4°C. After 
washing with PBS/Tween lck/fyn/MAPK blots were incubated with a 
horseradish peroxidase (HRPO)-coupled anti-mouse IgG (1:30,000; 
v/v) (Dianova, Hamburg, Germany). 4G10-biotin blots were incubated 
with streptavidin-biotinylated HRPO complex (1:5,000; v/v) (Amer- 
sham). All blots were developed with thechemiluminescence m thod 
ECL following the manufacturer's protocol (Amersham). 
2.4. Immunofluorescence 
For indirect immunofluorescence, 106cells were washed and resus- 
pended in 100/ll of affinity-purified antibody diluted in PBS, 5% fetal 
calf serum, 0.1% NaN3 (10/zg/ml). Cells were incubated for 30 rain on 
ice, washed and resuspended in 100/~1 of 1:200 diluted Phycoerythrine 
(PE)-conjugated goat anti-mouse IgG (Dianova), incubated for 30 rain 
on ice, washed again and analyzed on a FACScan (Becton Dickinson). 
2.5. Cell stimulation and cytotoxicity assay 
10 6 cells untreated or pretreated with Herb. A were incubated with 
10/zg/ml anti-APO-1 (5 x 105 cells/ml) for 4 h at 37°C unless otherwise 
stated in the figure legends. Quantification of DNA fragmentation to 
measure of apoptosis was carried out essentially as described elsewhere 
[211. 
3. Results and discussion 
It has been recently shown that TCR-induced apoptosis in- 
volves the APO-1 receptor/ligand system [22,23]. This process 
can be dissected into two sequential steps. (1) Triggering of the 
TCR/CD3-complex induces synthesis of the APO-1 ligand 
(APO-1L). (2) Secretion of the APO-1L and binding of APO- 
1L to the APO-1 receptor then induces apoptosis. In the leuke- 
mic T cell line Jurkat apoptosis can, therefore, be induced by 
stimulating either the TCR/CD3 complex or, alternatively, the 
APO-1 receptor directly (e.g. employing APO-1L or anti-APO- 
1 antibodies). Triggering the TCR results in a balanced activa- 
tion of PTKs such as p561ok and PTPases such as CD45 [16]. It 
has also been reported that direct triggering of the APO-1 
receptor in human Jurkat T cells involves activation of PTKs 
[11]. Since activation of the PTK pathway is a prerequisite for 
TCR/CD3-mediated T-lymphocyte activation, we were inter- 
ested to analyze whether the mechanisms underlying signalling 
via TCR/CD3 and APO-1 were similar. To this end we analyzed 
three Jurkat cell lines, wild type Jurkat cells, J45.01 and 
JCaM1.6, for their ability to undergo apoptosis following trig- 
gering of the APO-1 receptor. J45.01 is largely deficient in 
expression of CD45 [18] whereas JCaM1.6 is deficient in ex- 
pression of p56 l°k [13]. Both cell lines have previously been 
demonstrated to be strongly impaired in their ability to signal 
via the TCR/CD3 molecular complex, due to lack of expression 
of the two enzymes. The phenotype of both cell lines is depicted 
in Fig. 1 and Table 1, respectively. 
We first investigated the pattern of tyrosine phosphorylation 
following TCR/CD3 and APO-1 triggering in wild type Jurkat 
cells and the two mutant cell lines. As shown in Fig. 2A, stim- 
ulation of wild type Jurkat cells employing an anti-CD3 mAb 
resulted in rapid phosphorylation f a particular set of proteins 
on tyrosine residues. In agreement with previously published 
data no increase in tyrosine phosphorylation was detectable in
the two mutant Jurkat cell lines following CD3-mediated T-cell 
activation (Fig. 2A). Moreover, pervanadate reatment which 
has previously been shown to activate cytoplasmic PTKs 
through inhibition of PTPases [24] did hardly induce phospho- 
rylation of proteins in JCaM 1.6 cells whereas it lead to massive 
accumulation of tyrosine phosphorylated proteins in wild type 
Jurkat and J45.01 cells (Fig. 2C). Aside from being deficient in 
CD3-mediated signalling, JCaM 1.6 cells seem to have a general 
reduction in cytoplasmic PTK activity. Perhaps more impor- 
tantly, anti-APO-1 did not induce significant tyrosine phospho- 
rylation of cytosolic proteins in all tested cells (Fig. 2B) sug- 
gesting that APO-1 does not activate a classical PTK path- 
way. 
We next investigated J45.01 and JCaM 1.6 for their ability to 
undergo apoptosis following triggering of the APO-1 receptor. 
Fig. 3 demonstrates that both cell lines were equally sensitive 
towards anti-APO-1-induced apoptosis when compared to wild 
type Jurkat cells. All three cell lines were efficiently killed by 
10 ng/ml anti-APO-I (Fig. 3). These data suggest that APO-1- 
mediated signalling does neither depend on expression of p561¢k 
nor on expression of enzymatically active CD45. 
Since we could not exclude the possibility that activation of 
src-related kinases different from lck were responsible for in- 
duction of apoptosis in J45.01 and JCaM1.6 cells, we investi- 
gated whether Herb. A might inhibit this pathway in wild type 
Jurkat cells. Herb. A represents a non-competitive inhibitor of 
src-related PTKs and acts by directing them towards degrada- 
tion [25]. It has recently been reported to inhibit anti-APO-1- 
induced apoptosis at high concentrations [11]. Wild type Jurkat 
cells were incubated with DMSO alone or, alternatively, with 
increasing concentrations of Herb. A for 18 h. Subsequently, 
cells were stimulated with anti-APO-1 antibody for increasing 
periods of time. To confirm that src kinases were degraded 
under these conditions p56 lck and p59 fyn protein expression was 
determined by Western blotting. As shown in Fig. 4E a Herb. 
A concentration of 4 ¢tM was sufficient o completely degrade 
lck. p59 fyn was more resistant to the degrading effect of Herb. 
A. However, an in vitro kinase assay of fyn immunoprecipitates 
indicated complete suppression of enzymatic activity already at 
1 ¢tM Herb. A (data not shown). Importantly, concentrations 
of Herb. A up to 4/zM did not inhibit but rather augmented 
APO-l-mediated apoptosis (fig. 4A-C). Moreover, a concen- 
tration of 10 ¢tM Herb. A induced spontaneous apoptosis of 
p561ck.  
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Fig. 1. Characterization f Jurkat mutants J45.01 and JCaMI.6. 
2.5 x 105 cells were subjected to a Western blot analysis using an anti- 
lck antibody (upper panel). As an equal oading control the same blot 
was developed with an anti-MAPK antibody (center panel). CD45 
phosphatase activity was determined as described elsewhere [20]. The 
background was 0.01. 
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Fig. 2. Analysis of tyrosine-phosphorylated cytosolic proteins. A,B: 106 Jurkat cells were incubated with 10/~g/ml OKT3 (A) or with 10 ¢tg/ml 
anti-APO-I (B) and then subjected to an anti-phosphotyrosine W stern blot. The same blot was probed with an anti-MAPK antibody as a control 
for equal ane loading. C: Cells were incubated in the absence (-) or presence (+) of pervanadate for 15 min and the lysates from 2 x 105 cells were 
subjected to an anti-phosphotyrosine W stern blot analysis. 
almost 20% of the cells even in the absence of anti-APO-1 mAb 
(Fig. 4D). This strongly suggests that this Herb. A concentra- 
tion was toxic for the cells. These data are consistent with 
previous reports showing that a number of PTK inhibitors uch 
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Fig. 3. The lack of CD45 or p56 lek has no effect on anti-APO-l-induced 
sensitivity. 106 cells wt Jurkat (©), J45.01 (m) or JCaM1.6 (o) cells were 
incubated with different anti-APO-1 concentrations for 18 h. Apoptotic 
cells were determined as described in section 2. 
as Genistein, Herb. A and others can induce apoptosis in lym- 
phoid cells including Jurkat T cells [26-28]. Since it is now 
becoming clear that cells can only undergo anti-APO-l- induced 
cell death when their vitality is not affected, we interpret he 
failure of high concentrations of Herb. A to enhance apoptosis 
as being due to reduced viability of the cells. In this regard it 
is important o mention that a previous report could only dem- 
onstrate inhibition of anti-APO-l- induced apoptosis at Herb. 
A concentrations which inhibited cell growth [11]. Recently, a 
protein tyrosine phosphatase FAP-1 was identified that associ- 
ates with APO-1 and confers resistance to APO-l - induced ap- 
optosis [29]. However, since that enzyme is not expressed in 
Jurkat cells [29]. FAP-1 can not be crucial for the APO-1 
signalling pathway. 
Our data suggest hat tyrosine phosphorylation might not 
play a critical role during APO-l -mediated apoptosis. First, 
Table 1 
Analysis of surface molecules on Jurkat cells 
Cell line Control APO-1 CD45 CD3 
Wt Jurkat 2.2 (4) 99.7 (54) 99.3 (50) 94.2 (94) 
J45.01 1.1 (3) 98.3 (35) 6.2 (6) 99.2 (152) 
JCaM1.6 1.3 (3) 99.8 (49) 97.9 (31) 87.1 (79) 
In parenthesis: Mean fluorescence intensity. The following antibodies 
were used: anti-APO-l, OKT3 (anti-CD3) and AICD45.2 (anti-CD45). 
A Phycoerythrine-conjugated goatanti-mouse IgG antibody was used 
as second antibody. Controls were only stained with secondary anti- 
body. 
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Fig. 4. Effects of Herb. A on APO-l-dependent apoptosis ensitivity. 
A-D: Wt Jurkat cells were preincubated with 0.05% (A), 0.1% (B), 0.2% 
(C) or 0.5% DMSO in the absence (©) or presence of(e) 1 ]~M (A), 2 
/~M (B), 4/IM (C) or 10/.tM (D) Herb. A for 18 h and then incubated 
with 10 ¢tg/ml anti-APO-1. E: 5 x 106 Jurkat cells were preincubated 
with Herb. A at different concentrations for18 h. A Western blot using 
an antiserum directed at p56 ~ck (upper panel), at p59 ryn (center panel) 
or a mAb against he MAPK (lower panel). 
CD45 and p56 ~ck deficient Jurkat mutants (J45.01 and 
JCaM 1.6) were as sensitive towards APO-1-mediated signalling 
as their wild type counterparts. Second, no increase in tyrosine 
phosphorylation was detectable in the severely tyrosine phos- 
phorylation defective T cell mutant JCaM 1.6. Third, the classi- 
cal PTK inhibitor Herb. A did not inhibit but rather increased 
apoptosis at concentrations which completely inhibited src ki- 
nases. The previously published induction of PTK activity fol- 
lowing APO-1 triggering [11] could be due to a secondary in- 
duction of src related kinases in the tested cells and the ob- 
served inhibition of apoptosis by Herb. A could be due to the 
properties of tyrosine kinase inhibitors to induce apoptosis 
themselves. Therefore, we conclude that APO-1 mediated sig- 
nalling is fundamentally different from the classical TCR/CD3 
mediated pathway of human T-cell activation as it does not 
seem to depend on protein tyrosine phosphorylation. 
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